Development of new therapeutic strategies to prevent stem cell formation of glioblastoma by epigenetics control

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K10771
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Tokyo Women's Medical University
• Principal Investigator: Nitta Masayuki 東京女子医科大学, 医学部, 助教 (70588269)
• Co-Investigator(Kenkyū-buntansha): 丸山 隆志 東京女子医科大学, 医学部, 講師 (40301543) ; 赤川 浩之 東京女子医科大学, 医学部, 准教授 (60398807) ; 増井 憲太 東京女子医科大学, 医学部, 助教 (60747682) ; 安田 崇之 東京女子医科大学, 医学部, 助教 (70725366) ; 都築 俊介 東京女子医科大学, 医学部, 助教 (90746794)
• Research Collaborator: Muragaki Yoshihiro
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: glioblastoma / stem cell / cMyc / anti tumor effect

Outline of Final Research Achievements

The following results were obtained as a result of this research.
In glioblastoma, the expression of stem cell markers such as cMyc and Sox2 was higher at the time of relapse than at the time of relapse. This suggested that tumor recurrence is associated with stem cell formation of tumor cells. Next, when cultured cells from tumor tissue were established, and a drug that suppresses cMyc expression was administered using a cell line with high cMyc expression, and a DNA-damaging anticancer agent, it showed an antitumor effect against single drug administration. These findings form the basis for a treatment that suppresses stem cell formation in glioblastoma

Free Research Field

脳腫瘍

Academic Significance and Societal Importance of the Research Achievements

致死性が高く、有効な治療法が存在しない膠芽腫は平均生存期間が2年に満たない非常に悪性度の高い腫瘍で、腫瘍の中に存在する幹細胞が治療抵抗性の原因の一つと考えられている。今回の成果は、腫瘍の幹細胞化を抑制することを用いた新たな治療法の開発の基礎となったと考えられる